AASoci  Vol.6 No.1 , January 2016
Sickrole Compliance and Sickrole Deviance among Tuberculosis Patients on Treatment in Kanyama, a Zambian Shanty Compound
Abstract: Background: Kanyama compound has had a DOTS community based programme since 2012 where TB supporters in the community have been fostering the DOTS programme. Prior to this study, research had not been done using Parsonian sickrole behaviour concept to determine the pattern of deviance especially the sickrole behavioural responses on the part of people who were on TB treatment. Methods: This was an exploratory study and the study sample was drawn from a large mixed methods study (quan + QUAL) comprising of 457 men and women ≥15 years. Enrolees were disproportionately sampled using systematic sampling from a population of 1126 men and women who were on multi drug therapy over a two-year period. Categorical and numeric data from the tool was cleaned and analyzed by using SPSS version 21 (Inc., Chicago, USA). Statistical analysis was done using Pearson’s Chi square test and ANOVA. A p value of <0.05 was considered to be significant. Results: 18.5% of the enrolees honoured medical appointments when due whereas 81.5% did not. There was a significant association p < 0.05 with case type and marital status. 39.6% of the enrolees honoured the medical regimen by taking the prescribed drugs, 33.3% failed to honour and 27.1% were not sure. There was a significant association p < 0.05 between case type and marital status. Conclusions: Strengthening DOTS programs at community level through volunteers to enhance patient adherence to TB treatment and giving personalised attention to men and women who may be at risk of developing secondary tuberculosis, or risk for drug resistance and even dying is recommended. There is evidence to laud the great effort being expended by volunteer community based tuberculosis supporters in ensuring that what DOTS stands for is met.
Cite this paper: Mwanza, J. (2016) Sickrole Compliance and Sickrole Deviance among Tuberculosis Patients on Treatment in Kanyama, a Zambian Shanty Compound. Advances in Applied Sociology, 6, 1-11. doi: 10.4236/aasoci.2016.61001.

[1]   Ansari, M. S., Khayyam, K. U., Sharma, M., & Alam, S. (2013). The Contribution of Disease and Drug Related Factors to Non-Compliance with Directly Observed Treatment Short Course Among Tuberculosis Patients. African Journal of Pharmacy and Pharmacology, 7, 2466-2473.

[2]   Besch, C. L. (1995). Compliance in Clinical Trials. AIDS, 9, 1-10.

[3]   Birenbaum, A. (1984). Health Care and Society. New Jersey: Allanheld and Osmun.

[4]   Bissell, P., Trausen, M. J., & Haugbolle, L. S. (2002). Sociological Theory and Pharmacy Practice Research. An Introduction to Functionalist Sociology: Talcott Parsons’ Concept of the Sickrole. International Journal of Pharmacy Practice, 10, 60-68.

[5]   Bosman, M. C. (2000). Health Sector Reform and Tuberculosis Control: The Case of Zambia. The International Journal of Tuberculosis and Lung Disease, 4, 606-614.

[6]   Burman, W. J., Cohn, D. L., Rietmeijer, C. L., Judson, F. N., Sbarbaro, J. A., & Reves, R. R. (1997). Noncompliance with Directly Observed Therapy for Tuberculosis. Epidemiology and Effect on the Outcome of Treatment. Chest, 111, 1168-1173.

[7]   Cockerham, W. (2000). Medical Sociology. Upper Saddle River, NJ: Prentice-Hall.

[8]   Cockerham, W. C. (2001). Medical Sociology and Sociological Theory. In W.C. Cockerham (Ed.), The Blackwell Companion to Medical Sociology (pp. 3-22). Malden, MA: Blackwell Publishing.

[9]   Cramer, J. (1991). Overview of Methods to Measure and Enhance Patient Compliance. In J. Cramer & B. Spiker (Eds.), Patient Compliance in Medical Practice and Clinical Trials (pp. 3-10). New York: Raven Press.

[10]   Fox, R. (1989). The Sociology of Medicine: A Participant Observer’s View. Englewood.

[11]   Freidson, F. (1970). Profession of Medicine. New York: Harper and Row.

[12]   Grange, J. M., & Zumla, A. (2002). The Global Emergency of Tuberculosis: What Is the Cause? The Journal of the Royal Society for the Promotion of Health, 122, 78-81.

[13]   Jones, R. K. (1991). Sociology of Health and Illness. Kenwyn: Juta and Co. Ltd.

[14]   Khan, K., Pillay, T., Moodley, J. M., & Connolly, C. C. (2001). Maternal Mortality Associated with Tuberculosis-HIV-1 Co-Infection in Durban, South Africa. AIDS, 15, 1857-1863.

[15]   Maartens, G., & Wilkinson, R. J. (2007). Tuberculosis. The Lancet, 370, 2030-2043.

[16]   McKinlay, J. (1973). Social Networks, Lay Consultation and Help-Seeking Behaviour. Social Forces, 51, 275-279.

[17]   Mulenga, C., Shamputa, I. C., Mwakazanga, D., Kapata, N., Portaels, F., & Rigouts, R. (2010). Diversity of Mycobacterium Tuberculosis Genotypes Circulating in Ndola, Zambia. BMC Infectious Diseases, 10, 177.

[18]   O’Brien, M. K., Petrie, K., & Raeburn, J. (1992). Adherence to Medication Regimens: Updating a Complex Medical Issue. Medical Care Research and Review, 49, 435-454.

[19]   Parsons, T. (1951). The Social System. Glencoe, IL: The Free Press.

[20]   Parsons, T. (1978). Action Theory and the Human Condition. New York: Free Press.

[21]   Sarkar, S., & Suresh, M. R. (2011). An Overview of Tuberculosis Chemotherapy—A Literature Review. Journal of Pharmacy and Pharmaceutical Science, 14, 148-161.

[22]   Sharma, S. K., & Mohan, A. (2004). Multidrug-Resistant Tuberculosis. Indian Journal of Medical Research, 120, 354-376.

[23]   Srivastava, S., Pasipanodya, J. G., Meek, C., Leff, R., & Gumbo, T. T. (2011). Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability. The Journal of Infectious Diseases, 204, 1951-1959.

[24]   Trajman, A., Long, R., Zylberberg, D., Dion, M. J., Al-Otaibi, B., & Menzies, D. (2010). Factors Associated with Treatment Adherence in a Randomised Trial of Latent Tuberculosis Infection Treatment. The International Journal of Tuberculosis and Lung Disease, 14, 551-559.

[25]   Volmink, J., Matchaba, P., & Garner, P. (2000). Directly Observed Therapy and Treatment Adherence. The Lancet, 355, 1345-1350.

[26]   WHO (1994). WHO Report on the TB Epidemic. (WHO/TB/94.177), Geneva: World Health Organisation.

[27]   WHO (2006). World Health Organization. The Global Plan to Stop TB. 2006-2015: PART I Strategic Directions.

[28]   WHO (2008). World Health Organization Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organisation.

[29]   WHO (2010). Global Tuberculosis Control: WHO Report 2010. Geneva: World Health Organisation.

[30]   WHO (2014a). Antimicrobial Resistance: Global Report on Surveillance. Geneva: World Health Organisation.

[31]   WHO (2014b). Tuberculosis Control: The Situation in the African Region. 55th Session of the WHO Regional Committee for Africa, Maputo, 22-26 August 2005, AFR/RC55/20. Brazzaville: World Health Organization Regional Office for Africa; 2005.

[32]   Zai, S., Haroon, T., & Mehmood, K. T. (2010). Socioeconomic Factors Contributing to Multi-drug-Resistant Tuberculosis (MDR-TB). Journal of Biomedical Science and Research, 2, 279-283.

[33]   Zola, I. K. (1966). Culture and Symptoms: An Analysis of Patients Presenting Complaints. American Sociological Review, 31, 615-630.